In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 12 ( 2022-12-21), p. e0278951-
Abstract:
To assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro. Methods In vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced retinopathy (OIR) and the effect of multiple intraperitoneal injections of ranibizumab and aflibercept on neonatal mice were assessed. In vitro, the interaction of mouse VEGF-A with aflibercept or ranibizumab as the primary antibody was analyzed by Western blot. Results In both experiments using intravitreal injections in OIR mice and multiple intraperitoneal injections in neonatal mice, anti-VEGF effects were observed with aflibercept, but not with ranibizumab. Western blot analysis showed immunoreactive bands for mouse VEGF-A in the aflibercept-probed blot, but not in the ranibizumab-probed blot. Conclusions Aflibercept but not ranibizumab interacts with mouse VEGF, both in vivo and in vitro. When conducting experiments using anti-VEGF drugs in mice, aflibercept is suitable, but ranibizumab is not.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0278951
DOI:
10.1371/journal.pone.0278951.g001
DOI:
10.1371/journal.pone.0278951.g002
DOI:
10.1371/journal.pone.0278951.g003
DOI:
10.1371/journal.pone.0278951.s001
DOI:
10.1371/journal.pone.0278951.s002
DOI:
10.1371/journal.pone.0278951.s003
DOI:
10.1371/journal.pone.0278951.s004
DOI:
10.1371/journal.pone.0278951.r001
DOI:
10.1371/journal.pone.0278951.r002
DOI:
10.1371/journal.pone.0278951.r003
DOI:
10.1371/journal.pone.0278951.r004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2022
detail.hit.zdb_id:
2267670-3
Bookmarklink